ArticleAmerican journal of translational research2026
Effect of afatinib combined with induction chemotherapy on primary tumor regression and safety of surgical margins in locally advanced oral cancer.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the impact of afatinib in combination with induction chemotherapy on primary tumor regression, surgical margin security, and long-term prognostic outcomes in patients with locally advanced oral cancer (LAOC).
methodsA retrospective study was performed on 218 LAOC patients admitted to The Second Hospital of Lanzhou University and Integrated Traditional Chinese and Western Medicine Hospital of Tianshui City from 2016 to 2019, assigned to a combination group (afatinib + TPF, n=115) and a control group (TPF alone, n=103). Tumor regression (RECIST 1.1, pathological grading), positive margin rate, tumor markers, adverse reactions, and 5-year survival were analyzed and compared; Logistic and COX regression models were used to analyze risk factors.
resultsCombination group had higher ORR (70.43% vs. 57.28%, P=0.043), DCR (93.04% vs. 75.73%, P<0.001) and tumor regression ≥90% (33 vs. 16 cases, P<0.05), lower positive margin rate (14.78% vs. 37.86%, P<0.001), reduced postoperative tumor markers (all P<0.05), and better 5-year OS/DFS (all P<0.001). Afatinib combination was a protective factor for margin and survival, with no significant adverse responses (P>0.05).
conclusionAfatinib combined with induction chemotherapy enhances tumor regression effect, boosts surgical margin security, and lowers tumor marker levels without elevating adverse event risks, which acts as an effective neoadjuvant strategy for LAOC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.